Navigation Links
Drugs for Treating Congestive Heart Failure: Global Markets
Date:11/21/2011

NEW YORK, Nov. 21, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Drugs for Treating Congestive Heart Failure: Global Markets

http://www.reportlinker.com/p0687765/Drugs-for-Treating-Congestive-Heart-Failure-Global-Markets.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=NoCategory

REPORT SCOPE

INTRODUCTION

STUDY GOALS AND OBJECTIVES

The objectives of the study are to present a comprehensive look at the drugs for treating congestive heart failure (CHF)—global market measurements of both the overall market and all possible market segments, and to forecast market and segment growth during the next five years.

REASONS FOR STUDY

This BCC study will increase the awareness of drugs to treat congestive heart failure. The study analyzes the global market for select drugs for treating the congestive heart failure. It does so from different standpoints and addresses issues and trends affecting the market. Congestive heart failure drug manufacturers, driven by both research breakthroughs and increased recognition of expanding market opportunities, have stepped up the pace of development of innovative products. Because of the evolving nature of this important area of study, executives of product development for congestive heart failure drugs must remain ever vigilant of the changing environment and strive to keep abreast of new and currently used modalities in all facets of the market.

SCOPE OF STUDY

This report is a comprehensive business tool designed to provide an in-depth look at drugs for the congestive heart failure market. The geographic scope of the report is global with a special emphasis on individual regions. The report describes the industry, its relationship to the healthcare industry and its participants, and trends for the future.

Categories discussed in the report include:

* Angiotensin converting enzyme (ACE) inhibitors/angiotensin II receptor blocker antagonists (ARBs)

* Beta-adrenergic receptor blocking agents

* Diuretics

* Inotropic drugs/vasodilators

All categories are discussed in detail, describing each segment, identifying current products on the market, measuring market size, identifying market drivers, forecasting for 2010 to 2016, and assessing the competitors and competitor market shares.

METHODOLOGY AND INFORMATION SOURCES

Both primary and secondary research methodologies were used in preparing this study. The information and analysis presented in this BCC report are based on extensive first-hand interviews with primary research sources, including executives, product managers, and clinical specialists in the congestive heart failure drug development arena. Background information was obtained from various government agencies, business and medical journals, trade magazines, and interviews with doctors and nurses involved in the treatment of congestive heart failure.

Key information from published literature was used to conduct interviews with more than 20 industry participants to validate and obtain expert opinions on current and future trends in the congestive heart failure drug market. Interviews were the primary basis for development of market size. Interviews were also used to confirm and/or adjust market size and market share estimates, as well as formulating market projections.

All market data pertain to the global market at the manufacturer's level. Data are expressed in current U.S. dollars. The base year was 2011. Historical data are provided for 2010 and forecast data are provided for 2016. Historical, base year, and forecast data are provided for each market segment and subsegment. Market shares are provided for each market segment for the 2011 base year.

ANALYST CREDENTIALS

Mary Anne Crandall is an expert industry analyst specializing in the pharmaceutical industry for the last 20 years. She has completed several in-depth studies on various medical topics requiring both medical expertise and excellent knowledge of the pharmaceutical industry. Ms. Crandall has extensive knowledge in the medical field, has an M.S. in psychology, and is currently working on a PhD.

CHAPTER ONE: INTRODUCTION 1

STUDY GOALS AND OBJECTIVES . 1

REASONS FOR STUDY . 1

SCOPE OF STUDY . 1

METHODOLOGY AND INFORMATION SOURCES ... 2

ANALYST CREDENTIALS 2

RELATED BCC REPORTS 2

BCC ONLINE SERVICES .. 3

DISCLAIMER . 3

CHAPTER TWO: EXECUTIVE SUMMARY ... 4

EXECUTIVE SUMMARY ... 4

SUMMARY TABLE TOTAL GLOBAL MARKET SIZE AND FORECAST

FOR CHF PHARMACEUTICALS, THROUGH 2016 ($ MILLIONS) ... 5

GLOBAL SUMMARY FIGURE TOTAL GLOBAL MARKET SIZE AND

FORECAST FOR CHF PHARMACEUTICALS, 2010–2016 ($

MILLIONS) .. 6

EXECUTIVE SUMMARY (CONTINUED) . 7

CHAPTER THREE: OVERVIEW 8

ETIOLOGY .. 8

SYSTOLIC FAILURE .. 9

DIASTOLIC FAILURE .. 10

COMPENSATION 10

SYMPATHETIC NERVOUS SYSTEM ACTIVATION . 11

INCREASED PRELOAD ... 11

MYOCARDIAL HYPERTROPHY . 12

CLINICAL PRESENTATION OF CHF ... 12

LEFT-SIDED HEART FAILURE .. 12

RIGHT-SIDED HEART FAILURE 13

BIVENTRICULAR HEART FAILURE . 14

DEMOGRAPHICS 14

TABLE 1 TOTAL GLOBAL POPULATION BY SELECTED

GEOGRAPHIC REGION, 2000–2050 (MILLIONS/% CHANGE) . 15

FIGURE 1 TOTAL GLOBAL POPULATION BY SELECTED

GEOGRAPHIC REGION, 2000–2050 (MILLIONS) 16

TREATMENTS . 17

MANAGEMENT OF PRELOAD ... 17

MANAGEMENT OF AFTERLOAD .. 18

MANAGEMENT OF CONTRACTILITY... 18

ARB IMPACT ON ALZHEIMER'S DISEASE RISK 19

PRODUCTS ... 20

ACE INHIBITORS . 20

TABLE 2 SELECTED ACE INHIBITORS AVAILABLE FOR THE

TREATMENT OF CHF . 21

AccuprilAccupro ... 21

Aceon 21

Capoten 22

Coversyl 22

Lotensin ... 22

Mavik ... 22

Monopril ... 22

Prinivil/Zestril .. 23

Tarka 23

Tritace/Altace ... 23

Univasc . 23

Vasotec . 23

ANGIOTENSIN II RECEPTOR BLOCKERS ... 24

Atacand/Blopress . 24

Avapro/Avalide 24

Benicar . 24

Cozaar/Hyzaar . 25

Diovan-Co-Diovan 25

Micardis ... 26

Teveten . 27

TABLE 3 SELECTED ANGIOTENSIN II RECEPTOR BLOCKERS

AVAILABLE FOR THE TREATMENT OF CHF . 28

BETA-ADRENERGIC BLOCKING AGENTS .. 28

Betapace ... 28

Blocadren . 28

Brevibloc .. 29

Coreg 29

Corgard 29

Inderal .. 29

Kerlone . 29

Sectral .. 30

Tenormin .. 30

Toprol XL/Seloken ZOK/Betaloc . 30

Zebeta ... 30

TABLE 4 SELECTED BETA-ADRENERGIC RECEPTOR BLOCKING

AGENTS AVAILABLE FOR THE TREATMENT OF CHF . 31

DIURETICS 31

Carbonic Anhydrase Inhibitors ... 32

Thiazide and Thiazide-like Diuretics . 33

Diuril . 34

Enduron . 34

Hydrodiuril 34

Hygroton 34

Renese ... 34

Potassium-Sparing Diuretics .. 34

Aldactone ... 35

Dyrenium .. 35

Midamor 35

Loop Diuretics .. 35

Lasix .. 35

TABLE 5 SELECTED DIURETIC AGENTS AVAILABLE FOR THE

TREATMENT OF CHF . 36

POSITIVE INOTROPICS .. 37

Inocor 38

Lanoxicaps/Lanoxin . 38

TABLE 6 SELECTED POSITIVE INOTROPIC DRUGS AVAILABLE

FOR THE TREATMENT OF CHF 39

VASODILATORS ... 39

ISMO 40

Nitro-Dur Transdermal ... 40

Nitrostat ... 40

TABLE 7 SELECTED VASODILATORS AVAILABLE FOR THE

TREATMENT OF CHF . 40

RESEARCH AND DEVELOPMENT ... 41

BYSTOLIC .. 41

GENCARO .. 41

JENLOGA XR . 41

LIXIVAPTAN . 42

LCZ696 42

RLX030 ... 42

TEKTURNA 43

MYOCELL .. 43

ALBIGLUTIDE .. 43

ALD-201 .. 43

ALLOGENIC ADULT STEM CELL .. 44

AMG 423 . 44

IK-5001 ... 44

IROXANADINE .. 44

PL-3994 ... 44

SLX2101 .. 45

UROCORTIN 2 ... 45

ADX415 ... 45

GLIAL GROWTH FACTOR 2 45

JVS-100 ... 46

BR-4628 .. 46

MYOBLAST THERAPY . 46

TABLE 8 PRODUCTS IN DEVELOPMENT TO TREAT CHF ... 47

CHAPTER FOUR: THE GLOBAL MARKET 48

THE GLOBAL MARKET .. 48

TABLE 9 GLOBAL MARKET FORECAST FOR CHF

PHARMACEUTICALS BY REGION, THROUGH 2016 ($ MILLIONS) ... 49

FIGURE 2 GLOBAL MARKET FORECAST FOR CHF

PHARMACEUTICALS BY REGION, 2010–2016 ($ MILLIONS) .. 50

GROWTH BY GEOGRAPHIC REGION .. 50

TABLE 10 GLOBAL MARKET SHARES OF CHF PHARMACEUTICAL

REVENUES BY REGION, 2011 (%) 51

FIGURE 3 GLOBAL MARKET SHARES OF CHF PHARMACEUTICAL

REVENUES BY REGION, 2011 (%) 51

GROWTH BY DRUG CLASS ... 51

GROWTH BY DRUG CLASS (CONTINUED) .. 52

TABLE 11 GLOBAL CHF MARKET BY DRUG TYPE, THROUGH 2016

($ MILLIONS) 53

FIGURE 4 GLOBAL CHF MARKET BY DRUG TYPE, 2010-2016 ($

MILLIONS) 53

TABLE 12 GLOBAL CHF MARKET SHARES BY DRUG TYPE, 2011 (%) ... 54

FIGURE 5 GLOBAL CHF MARKET SHARES BY DRUG TYPE, 2011 (%) ... 55

TABLE 13 GLOBAL CHF MARKET SHARES BY DRUG TYPE, 2016 (%) ... 55

FIGURE 6 GLOBAL CHF MARKET SHARES BY DRUG TYPE, 2016 (%) ... 56

COMPETITIVE ANALYSIS . 56

TABLE 14 GLOBAL CHF PHARMACEUTICAL MARKET BY

COMPANY, 2011 ($ MILLIONS) .. 57

FIGURE 7 GLOBAL CHF PHARMACEUTICAL MARKET SHARES BY

COMPANY, 2011 (%) . 58

TABLE 15 GLOBAL CHF MANUFACTURER PRODUCT

PARTICIPATION BY DRUG TYPE . 58

TABLE 15 (CONTINUED) .. 59

CHAPTER FIVE: THE AMERICAS MARKET . 60

REGIONAL MARKETS 60

NORTH AMERICA 60

United States ... 60

Canada . 61

LATIN AND SOUTH AMERICA ... 62

Brazil 63

Brazil (Continued) 64

Brazil (Continued) 65

Mexico .. 66

Venezuela . 67

Argentina . 68

Peru, Officially the Republic of Peru .. 68

Chile . 69

Colombia .. 70

Cuba . 71

CHF POPULATION.. 71

TABLE 16 CHF POPULATION IN THE AMERICAS BY COUNTRY,

2011 72

REGIONAL DEMOGRAPHICS ... 72

NORTH AMERICA 72

United States ... 72

TABLE 17 U.S.' OLDER POPULATION BY AGE GROUP AND CENSUS

YEAR, 2000–2050 ... 72

TABLE 17 (CONTINUED) .. 73

Canada . 73

TABLE 18 CANADA'S OLDER POPULATION BY AGE GROUP AND

CENSUS YEAR, 2000–2050 . 73

LATIN AND SOUTH AMERICA ... 74

Brazil 74

TABLE 19 BRAZIL'S OLDER POPULATION BY AGE GROUP AND

CENSUS YEAR, 2000–2050 . 74

Mexico .. 75

TABLE 20 MEXICO'S OLDER POPULATION BY AGE GROUP AND

CENSUS YEAR, 2000–2010 . 75

Venezuela . 75

TABLE 21 VENEZUELA'S OLDER POPULATION BY AGE GROUP

AND CENSUS YEAR, 2000–2050 . 76

Argentina . 76

TABLE 22 ARGENTINA'S OLDER POPULATION BY AGE GROUP AND

CENSUS YEAR, 2000–2050 .. 76

Peru .. 77

TABLE 23 PERU'S OLDER POPULATION BY AGE GROUP AND

CENSUS YEAR, 2000–2050 . 77

Chile . 77

TABLE 24 CHILE'S OLDER POPULATION BY AGE GROUP AND

CENSUS YEAR, 2000–2050 . 78

Colombia .. 78

TABLE 25 COLOMBIA'S OLDER POPULATION BY AGE GROUP AND

CENSUS YEAR, 2000–2050 .. 78

Cuba . 79

TABLE 26 CUBA'S OLDER POPULATION BY AGE GROUP AND

CENSUS YEAR, 2000–2050 . 79

AMERICAS CHF MARKET FORECAST 79

TABLE 27 AMERICAS CHF PHARMACEUTICAL MARKET BY

GEOGRAPHIC REGION, THROUGH 2016 ($ MILLIONS) ... 80

FIGURE 8 AMERICAS CHF MARKET BY GEOGRAPHIC REGION,

2011 ($ MILLIONS) ... 80

TABLE 28 AMERICAS CHF MARKET BY DRUG TYPE, THROUGH

2016 ($ MILLIONS) ... 81

TABLE 29 AMERICAS CHF MARKET SHARES BY DRUG TYPE, 2011

(%) ... 82

FIGURE 9 AMERICAS CHF MARKET SHARES BY DRUG TYPE, 2011

(%) ... 82

TABLE 30 AMERICAS CHF MARKET SHARES BY DRUG TYPE, 2016

(%) ... 83

FIGURE 10 AMERICAS CHF MARKET SHARES BY DRUG TYPE, 2016

(%) ... 83

TABLE 31 U.S. CHF MARKET BY DRUG TYPE, THROUGH 2016 ($

MILLIONS) 84

TABLE 32 CANADIAN CHF MARKET BY DRUG TYPE, THROUGH

2016 ($ MILLIONS) ... 84

TABLE 33 LATIN AMERICAN/SOUTH AMERICAN CHF MARKET BY

DRUG TYPE, THROUGH 2016 ($ MILLIONS) ... 85

CHAPTER SIX: THE EUROPEAN MARKET .. 86

REGIONAL MARKETS 86

FRANCE . 86

France (Continued) .. 87

GERMANY . 88

ITALY . 89

Italy (Continued) . 90

SPAIN . 91

UNITED KINGDOM .. 91

United Kingdom (Continued) .. 92

United Kingdom (Continued) .. 93

TABLE 34 EUROPEAN CHF POPULATION BY COUNTRY, 2011... 94

REGIONAL DEMOGRAPHICS ... 94

FRANCE . 94

TABLE 35 FRANCE'S OLDER POPULATION BY AGE GROUP AND

CENSUS YEAR, 2000–2050 . 94

GERMANY . 95

TABLE 36 GERMANY'S OLDER POPULATION BY AGE GROUP AND

CENSUS YEAR, 2000–2050 .. 95

ITALY . 95

TABLE 37 ITALY'S OLDER POPULATION BY AGE GROUP AND

CENSUS YEAR, 2000–2050 . 96

SPAIN . 96

TABLE 38 SPAIN'S OLDER POPULATION BY AGE GROUP AND

CENSUS YEAR, 2000–2050 .. 97

UNITED KINGDOM .. 97

TABLE 39 U.K.'S OLDER POPULATION BY AGE GROUP AND

CENSUS YEAR, 2000–2050 . 97

EUROPEAN MARKET FORECAST 98

TABLE 40 EUROPEAN CHF PHARMACEUTICALS MARKET BY

GEOGRAPHIC REGION, THROUGH 2016 ($ MILLIONS) ... 99

FIGURE 11 EUROPEAN CHF PHARMACEUTICALS MARKET BY

GEOGRAPHIC REGION, 2011 ($ MILLIONS) . 100

FIGURE 12 EUROPEAN CHF PHARMACEUTICALS MARKET BY

GEOGRAPHIC REGION, 2016 ($ MILLIONS) . 100

TABLE 41 EUROPEAN CHF MARKET BY DRUG TYPE, THROUGH

2016 ($ MILLIONS) . 101

TABLE 42 EUROPEAN MARKET SHARES OF CHF

PHARMACEUTICALS BY TYPE, 2011 (%) .. 101

FIGURE 13 EUROPEAN MARKET SHARES OF CHF

PHARMACEUTICALS BY TYPE, 2011 (%) .. 102

TABLE 43 EUROPEAN MARKET SHARES OF CHF

PHARMACEUTICALS BY TYPE, 2016 102

FIGURE 14 EUROPEAN MARKET SHARES OF CHF

PHARMACEUTICALS BY TYPE, 2016 (%) .. 103

TABLE 44 CHF MARKET IN FRANCE BY DRUG TYPE, THROUGH

2016 ($ MILLIONS) . 103

TABLE 45 CHF MARKET IN GERMANY BY DRUG TYPE, THROUGH

2016 ($ MILLIONS) . 104

TABLE 46 CHF MARKET IN ITALY BY DRUG TYPE, THROUGH 2016

($ MILLIONS) .. 104

TABLE 47 CHF MARKET IN SPAIN BY DRUG TYPE, THROUGH 2016

($ MILLIONS) .. 105

TABLE 48 U.K. CHF MARKET BY DRUG TYPE, THROUGH 2016 ($

MILLIONS) .. 105

CHAPTER SEVEN: THE ASIAN MARKET ... 106

THE ASIAN MARKET ... 106

TABLE 49 ASIAN CHF POPULATION BY COUNTRY, 2011 .. 107

DEMOGRAPHICS .. 107

JAPAN .. 107

TABLE 50 JAPAN'S OLDER POPULATION BY AGE GROUP AND

CENSUS YEAR, 2000–2050 ... 108

CHINA .. 108

TABLE 51 CHINA'S OLDER POPULATION BY AGE GROUP AND

CENSUS YEAR, 2000–2050 ... 108

REGIONAL MARKETS .. 109

JAPAN .. 109

CHINA .. 110

China (Continued) . 111

China (Continued) . 112

ASIAN CHF MARKET FORECAST .. 113

TABLE 52 ASIAN CHF MARKET BY GEOGRAPHIC REGION,

THROUGH 2016 ($ MILLIONS) . 114

FIGURE 15 ASIAN CHF MARKET BY GEOGRAPHIC REGION, 2011 ($

MILLIONS) .. 114

FIGURE 16 ASIAN CHF MARKET BY GEOGRAPHIC REGION, 2016 ($

MILLIONS) .. 115

TABLE 53 ASIAN CHF MARKET BY DRUG TYPE, THROUGH 2016 ($

MILLIONS) .. 115

TABLE 54 ASIAN CHF MARKET SHARES BY DRUG TYPE, 2011 (%) . 116

FIGURE 17 ASIAN CHF MARKET SHARES BY DRUG TYPE, 2011 (%) .. 116

TABLE 55 ASIAN CHF MARKET SHARES BY DRUG TYPE, 2016 (%) . 117

FIGURE 18 ASIAN CHF MARKET SHARES BY DRUG TYPE, 2016 (%) .. 117

TABLE 56 JAPAN'S CHF MARKET BY DRUG TYPE, THROUGH 2016

($ MILLIONS) .. 118

TABLE 57 CHINA'S CHF MARKET BY DRUG TYPE, THROUGH 2016

($ MILLIONS) .. 118

CHAPTER EIGHT: REST-OF-WORLD/EMERGING MARKETS . 119

REGIONAL DEMOGRAPHICS . 119

TABLE 58 THE REST OF THE WORLD'S CHF POPULATION BY

COUNTRY, 2011 .. 119

AUSTRALIA . 119

TABLE 59 AUSTRALIA'S OLDER POPULATION BY AGE GROUP AND

CENSUS YEAR, 2000–2050 120

INDIA ... 120

TABLE 60 INDIA'S OLDER POPULATION BY AGE GROUP AND

CENSUS YEAR, 2000–2050 ... 121

ISRAEL . 121

TABLE 61 ISRAEL'S OLDER POPULATION BY AGE GROUP AND

CENSUS YEAR, 2000–2050 ... 121

RUSSIA . 122

TABLE 62 RUSSIA'S OLDER POPULATION BY AGE GROUP AND

CENSUS YEAR, 2000–2050 ... 122

REGIONAL MARKETS .. 122

AUSTRALIA . 122

INDIA ... 123

India (Continued)... 124

India (Continued)... 125

ISRAEL . 126

Israel (Continued) .. 127

RUSSIA . 128

ROW MARKET FORECAST .. 129

INDIA ... 129

ISRAEL/MIDDLE EAST .. 129

AUSTRALIA . 130

RUSSIA . 130

TABLE 63 REST OF WORLD CHF PHARMACEUTICAL MARKET BY

GEOGRAPHIC REGION, THROUGH 2016 ($ MILLIONS) . 131

FIGURE 19 REST OF WORLD CHF PHARMACEUTICAL MARKET BY

GEOGRAPHIC REGION, 2010-2016 ($ MILLIONS) 131

TABLE 64 REST OF WORLD CHF MARKET BY DRUG TYPE,

THROUGH 2016 ($ MILLIONS) . 132

TABLE 65 REST OF WORLD CHF MARKET SHARES BY DRUG TYPE,

2011 (%) 132

FIGURE 20 REST OF WORLD CHF MARKET SHARES BY DRUG

TYPE, 2011 (%) 133

TABLE 66 REST OF WORLD CHF MARKET SHARES BY DRUG TYPE,

2016 .. 133

FIGURE 21 REST OF WORLD CHF MARKET SHARES BY DRUG

TYPE, 2016 (%) 134

TABLE 67 AUSTRALIAN CHF MARKET BY DRUG TYPE, THROUGH

2016 ($ MILLIONS) . 134

TABLE 68 INDIA'S CHF MARKET BY DRUG TYPE, THROUGH 2016 ($

MILLIONS) .. 135

TABLE 69 ISRAEL/THE MIDDLE EAST'S CHF MARKET BY DRUG

TYPE, THROUGH 2016 ($ MILLIONS) . 135

TABLE 70 RUSSIAN CHF MARKET BY DRUG TYPE, THROUGH 2016

($ MILLIONS) .. 136

TABLE 71 OTHER CHF MARKETS BY DRUG TYPE, THROUGH 2016

($ MILLIONS) .. 136

CHAPTER NINE COMPANY PROFILES ... 137

ABBOTT LABORATORIES 137

HISTORY .. 137

PRODUCTS .. 138

REVENUE HISTORY .. 138

LOCATIONS . 138

CORPORATE MANAGEMENT .. 138

ARCA BIOPHARMA ... 139

HISTORY .. 139

PRODUCTS .. 139

REVENUE HISTORY .. 139

CORPORATE MANAGEMENT .. 139

ASTRAZENECA .. 140

HISTORY .. 140

PRODUCTS .. 140

REVENUE HISTORY .. 141

LOCATIONS . 141

CORPORATE MANAGEMENT .. 141

AUROBINDO PHARMA . 141

HISTORY .. 141

PRODUCTS .. 141

REVENUE HISTORY .. 142

LOCATIONS . 142

CORPORATE MANAGEMENT .. 142

BAYER AG .. 142

HISTORY .. 142

PRODUCTS .. 143

REVENUE HISTORY .. 143

LOCATIONS . 143

CORPORATE MANAGEMENT .. 143

BIOHEART, INC. 144

HISTORY .. 144

PRODUCTS .. 144

REVENUE HISTORY .. 144

LOCATIONS . 144

CORPORATE MANAGEMENT .. 145

BOEHRINGER INGELHEIM GMBH ... 145

HISTORY .. 145

PRODUCTS .. 145

REVENUE HISTORY .. 145

LOCATIONS . 146

CORPORATE MANAGEMENT .. 146

BRISTOL-MYERS SQUIBB CO. 146

HISTORY .. 146

PRODUCTS .. 147

REVENUE HISTORY .. 147

LOCATIONS . 147

CORPORATE MANAGEMENT .. 147

CARDIOKINE, INC. ... 147

HISTORY .. 148

PRODUCTS .. 148

REVENUE HISTORY .. 148

LOCATIONS . 148

CORPORATE MANAGEMENT .. 148

DR. REDDY'S LABORATORIES, LTD. . 148

HISTORY .. 149

PRODUCTS .. 149

REVENUE HISTORY .. 149

CORPORATE MANAGEMENT .. 149

FOREST LABORATORIES, INC. .. 149

HISTORY .. 150

PRODUCTS .. 151

REVENUE HISTORY .. 151

LOCATIONS . 151

CORPORATE MANAGEMENT .. 151

GLAXOSMITHKLINE 151

HISTORY .. 152

PRODUCTS .. 152

REVENUE HISTORY .. 152

LOCATIONS . 152

CORPORATE MANAGEMENT .. 153

MERCK ... 153

HISTORY .. 153

PRODUCTS .. 153

REVENUE HISTORY .. 154

LOCATIONS . 154

CORPORATE MANAGEMENT .. 154

MITSUBISHI TANABE PHARMA CORP. 154

HISTORY .. 155

PRODUCTS .. 155

REVENUE HISTORY .. 155

LOCATIONS . 155

CORPORATE MANAGEMENT .. 155

MYLAN, INC. .. 155

HISTORY .. 156

PRODUCTS .. 156

REVENUE HISTORY .. 156

CORPORATE MANAGEMENT .. 156

NEUROCRINE BIOSCIENCES . 157

HISTORY .. 157

PRODUCTS .. 157

REVENUE HISTORY .. 157

CORPORATE MANAGEMENT .. 157

NOVARTIS .. 158

HISTORY .. 158

PRODUCTS .. 158

REVENUE HISTORY .. 159

LOCATIONS . 159

CORPORATE MANAGEMENT .. 159

PFIZER, INC. .. 159

HISTORY .. 159

PRODUCTS .. 160

REVENUE HISTORY .. 160

CORPORATE MANAGEMENT .. 160

SANOFI-AVENTIS, INC. ... 161

HISTORY .. 161

PRODUCTS .. 161

REVENUE HISTORY .. 162

LOCATIONS . 162

CORPORATE MANAGEMENT .. 162

SERVIER . 162

HISTORY .. 162

PRODUCTS .. 162

REVENUE HISTORY .. 163

LOCATIONS . 163

CORPORATE MANAGEMENT .. 163

SHIONOGI & CO., LTD. 163

HISTORY .. 163

PRODUCTS .. 164

REVENUE HISTORY .. 164

LOCATIONS . 164

CORPORATE MANAGEMENT .. 164

TAKEDA PHARMACEUTICALS CO., LTD. . 164

HISTORY .. 165

PRODUCTS .. 165

REVENUE HISTORY .. 166

LOCATIONS . 166

CORPORATE MANAGEMENT .. 166

TEVA ... 166

HISTORY .. 166

PRODUCTS .. 167

REVENUE HISTORY .. 167

LOCATIONS . 167

CORPORATE MANAGEMENT .. 167

APPENDIX: DIRECTORY OF COMPANIES .. 168

APPENDIX: DIRECTORY OF COMPANIES 168

To order this report:

: Drugs for Treating Congestive Heart Failure: Global Markets

More  Market Research Report

Check our  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Ampio Pharmaceuticals Expands Patent Portfolio of Drugs for Treating Inflammatory Diseases
2. MedBox Develops Patent-Pending System for Storage and Retrieval of Prescription Drugs
3. Westside Medical Imaging Uses High Resolution Magnetic Imaging to Monitor Effects of Cholesterol Drugs on Atherosclerosis
4. China Nepstar Chain Drugstore to Report Third Quarter 2011 Financial Results on November 28
5. Pharmaceutical Pricing and Reimbursement in Europe - Reference Pricing and Similar Initiatives Being Applied to Innovative Drugs Pose Significant Challenge to Pharmaceutical Companies
6. Breaking Study: ICU Medical, Inc. ChemoClave® System Costs Less to Implement than any Closed System Transfer Device for the Safe Handling of Hazardous Drugs
7. FDA: 35 Innovative New Drugs Approved in Fiscal Year 2011
8. Generic Drugs: World Market Outlook 2011-2021
9. Multi-therapy Drugs: Opportunities for Generics & Biosimilars
10. The Global Market for Diabetes Drugs and Devices is Booming: Expected to Attain a Market Size of USD 114.3 Billion by 2016
11. FTC Study Finds that in FY 2011, Pharmaceutical Industry Continued to Make Numerous Business Deals that Delay Consumers Access to Lower-Cost Generic Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Consumers have taken ... regulators/payers have placed more emphasis on patient outcomes. ... support programs in the pharmaceutical industry have evolved ... Consequently, pharmaceutical companies are focusing on becoming more ... providing products and services that improve health. ...
(Date:6/24/2016)... Research and Markets has ... 2015-2025: Applications, Technologies, Forecasts" report to their ... Electronics, Smart Skin, Structural Health Monitoring, Composite Smart ... electronics involves electronic and/or electrical components and circuits ... structures such as vehicle bodies or conformally placed ...
(Date:6/24/2016)... 2016 According to a new ... Pen Needles, Safety Pen Needles), Needle Length (4mm, 5mm, ... Mode of Purchase (Retail, Non-Retail) - Trends & Global ... the market for the forecast period of 2016 to ... Billion by 2021 from USD 1.65 Billion in 2016, ...
Breaking Medicine Technology:
(Date:6/26/2016)... , ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal ... personalized through a fitness app. The fitness app plans to fix the two major problems ... offer a one size fits all type program , They don’t eliminate all ...
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... ... 2016 , ... First Choice Emergency Room , the largest network of ... Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased to ... said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
Breaking Medicine News(10 mins):